Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 4

Study Type

Interventional 80Observational 4Expanded_access 2

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × abemaciclib × Clear all
NCT06830720 2026-05-08

CAROLEEN

Novartis

Recruiting
3,250 enrolled
Breast

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Pfizer

Active not recruiting
1 enrolled
Breast

Breast Neoplasms

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Novartis

Completed
4,320 enrolled
Breast

Breast Neoplasms

NCT05141240 2021-12-16

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Novartis

Completed
4,650 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡